Johnson & Johnson is making a huge investment in the future of healthcare with the groundbreaking of a new biologics facility in Wilson, North Carolina. With a price tag of $2 billion, this cutting-edge plant is poised to revolutionize the production of therapies for cancer, immune diseases, and neurological conditions. It’s a bold move that not only strengthens the company’s role in pharmaceutical innovation but also marks a significant milestone for the region’s growing biotech sector.

This facility is part of Johnson & Johnson’s $55 billion commitment to boost U.S. manufacturing. Located on a 200-acre site, the plant will be equipped with the latest technology to enhance the efficiency and scalability of biologic medicine production. The goal? To get life-saving treatments to patients faster and more reliably.

“This new facility in Wilson will enable us to create and manufacture a range of life-changing therapies with greater speed and flexibility,” said a Johnson & Johnson spokesperson. “It also helps us build a more resilient supply chain for critical medicines.”

Unlike traditional pharmaceutical plants that focus on chemical-based drugs, the new Wilson facility will specialize in biologic therapies—medicines created from living cells. These therapies require highly specialized manufacturing processes, which the new facility is designed to handle.

Key features of the plant include:

• Automated  production lines to increase precision and efficiency

• Next-generation bioreactors to support large-scale cell culture growth

• Real-time quality monitoring systems to ensure the highest standards of safety and effectiveness

• Sustainable energy solutions to minimize environmental impact, aligning with J&J’s global sustainability goals

Once fully operational, this facility is set to be one of the most advanced biologics manufacturing plants in the U.S.

Biologic drugs are transforming how we treat some of the most challenging health conditions. At the new Wilson facility, Johnson & Johnson will focus on treatments for:

• Cancer: Precision therapies that target tumors with fewer side effects

• Immune-mediated diseases: Treatments for conditions like rheumatoid arthritis and psoriasis

• Neurological disorders: Therapies for Alzheimer’s, multiple sclerosis, and other      neurological diseases

By ramping up production, the company aims to accelerate the development and availability of these groundbreaking treatments, bringing new hope to patients around the world.

North Carolina has long been a hub for biotechnology, and Johnson & Johnson’s new facility further solidifies the state’s importance in the future of medicine. The project is expected to create more than 500 permanent high-tech jobs in biomanufacturing and 5,000 construction jobs as the facility is built.

“This project is a game-changer for both Wilson and North Carolina,” said a local economic development official. “It’s bringing good jobs to the area and positioning our state as a leader in the biotech and pharmaceutical industries.”

With the new biologics facility, Johnson & Johnson is taking a giant step toward reshaping how biologic treatments are produced and distributed. This investment is not just about cutting-edge technology—it’s about improving the lives of patients who depend on these therapies. As the facility nears completion, the impact will be felt far beyond Wilson, paving the way for more innovative treatments to reach those who need them most.

For more details on Johnson & Johnson’s manufacturing efforts, visit their media center